Individualizing dosing of irinotecan.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20068075.
- Also identified by DOI 10.1158/1078-0432.CCR-09-2936.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Individualized drug dosing is a longstanding goal of clinical pharmacologists. Given the narrow therapeutic index of most anticancer agents, it is plausible that this approach would be of particular value in oncology. Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors.
Medical subject headings
- Camptothecin
- Drug Dosage Calculations
- Neoplasms
- Precision Medicine